Argitalpenak (42) JOSE JAVIER ARAIZ IRIBARREN argitalpenak

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Absceso subretiniano por Nocardia en paciente inmunodeprimido: a propósito de un caso

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 656-659

  3. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

2022

  1. Evaluation of Macular Thickness Changes after Uncomplicated Phacoemulsification Surgery in Healthy Subjects and Diabetic Patients without Retinopathy by Spectral Domain OCT

    Diagnostics, Vol. 12, Núm. 12

  2. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world

    Acta ophthalmologica, Vol. 100, Núm. 2, pp. e521-e531

2021

  1. Plasma Rich in Growth Factors (PRGF) Increases the Number of Retinal Müller Glia in Culture but Not the Survival of Retinal Neurons

    Frontiers in Pharmacology, Vol. 12

  2. The Effect of Plasma Rich in Growth Factors on Microglial Migration, Macroglial Gliosis and Proliferation, and Neuronal Survival

    Frontiers in Pharmacology, Vol. 12

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

  2. Comparative lipidomic analysis of mammalian retinal ganglion cells and Müller glia in situ and in vitro using High-Resolution Imaging Mass Spectrometry

    Scientific Reports, Vol. 10, Núm. 1

  3. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?

    Lupus, Vol. 29, Núm. 7, pp. 671-675

  4. Genetic and environmental factors related to the development of myopic maculopathy in Spanish patients

    PloS one, Vol. 15, Núm. 7, pp. e0236071

2018

  1. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

    Journal of Ophthalmology, Vol. 2018

  2. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

  3. The retina of osteopontin deficient mice in aging

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 213-221

2016

  1. Casos clínicos en oftalmología: problemas diagnósticos en patología retinocoroidea zuz.

    Euromedice

  2. Evaluation of 10 AMD Associated polymorphisms as a cause of choroidal neovascularization in highly myopic eyes

    PLoS ONE, Vol. 11, Núm. 9

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  2. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia six years outcome

    Retina, Vol. 35, Núm. 12, pp. 2450-2456

  3. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014